Innovation for Sustainable Growth

J.P. Morgan Healthcare Conference
10 January 2022
Forward Looking Statements

Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilead's business, financial condition and results of operations; the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales and Gilead's ability to effectively manage the global supply and distribution of Veklury; Gilead's ability to achieve its anticipated full year 2021 financial results, including as a result of potential adverse revenue impacts from COVID-19, increases in R&D expenses and potential revenues from Veklury; Gilead's ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead's ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead's ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, and the possibility of unfavorable results from ongoing and additional clinical trials; the risk that safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates or the product candidates of Gilead's strategic partners; Gilead's ability to submit new drug applications for new product candidates in the currently anticipated timelines; Gilead's ability to receive regulatory approvals in a timely manner or at all, and the risk that any such approvals may be subject to significant limitations on use; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCovy®, DESCovy FOR PREP®, EMTRIVA®, EPCLUSA®, EviPLERA®, GENVOYA®, HARVONI®, HepCLiDEX® (BULEVIRTIDE), Hepsera®, Jyseleca®, LETAIRIS®, ODEFSEY®, Ranexa®, Sovaldi®, StirBild®, TecARTUS®, TRODELY®, TRUVADA®, TRUVADA FOR PREP®, Tymbost®, Veklury®, VeMlidy®, Viread®, Vosevi®, Yescarta® and Zydelig®. This report may also refer to trademarks, service marks and trade names of other companies.
### Gilead Today: Accelerating Path to Sustainable Growth

<table>
<thead>
<tr>
<th>2019</th>
<th>TODAY</th>
<th>2030</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Stabilized post-HCV decline</td>
<td>• Growing HIV revenues</td>
<td>• Expanding virology leadership: expect stable or growing HIV business</td>
</tr>
<tr>
<td>• Virology &gt;90% of revenue</td>
<td>• Executing on oncology strategy, tracking to exceed $1B in revenue</td>
<td>• Delivering a world-class oncology portfolio: expect to be a third of revenues</td>
</tr>
<tr>
<td>• Oncology &lt;5% of revenue</td>
<td>• Nearly doubled clinical pipeline</td>
<td>• Targeting 10+ transformative therapies by 2030</td>
</tr>
<tr>
<td>• Transitioned leadership and strategy</td>
<td>• Key role in helping to combat COVID</td>
<td></td>
</tr>
</tbody>
</table>
Expanding Virology Leadership Across Portfolio

**VIRAL HEPATITIS**

- **$2.2B**
  - Q321 YTD SALES
  - HCV Market Share
    - ~60% in U.S.
    - ~50% in EU
  - First Conditionally Approved Treatment in EU for HDV

**EMERGING VIROLOGY**

- **$4.2B**
  - Q321 YTD SALES
  - Veklury as Standard of Care for Hospitalized Patients
  - First FDA Approved Treatment for COVID-19

**HIV**

- **$11.8B**
  - Q321 YTD SALES
  - Biktarvy #1 Prescribed Treatment in U.S.
  - ~75% HIV Tx Market Share in U.S.
  - Descovy Maintains ~45% PrEP Market Share

---

**HIV Franchise Well-Positioned For Growth**

### TREATMENT

- **$6B Biktarvy Q321 YTD sales; 17% YoY growth**
- **~75% On GILD-based Tx regimen in 2021**
- Biktarvy patent expiration in 2033<sup>1</sup>
- Future long-acting options to sustain HIV business

### PREVENTION

- Market back to growth
- Only ~20% penetrated today in U.S.<sup>2</sup>
- Future long-acting options to potentially catalyze PrEP market growth in mid-2020s
- ~45% On Descovy for PrEP in 2021<sup>3</sup>

---

**Note:**
  1 Estimated patent expiry corresponds to the latest expiring compound patent for one of the active ingredients in the single tablet regimen.  
  3 Reflects HIV PrEP regimen market share in the U.S. Source: Weekly IQVIA NPA/NSP
HIV: Sustainable Revenue Through 2030 and Beyond

Evolution of Gilead’s HIV business

- Biktarvy growth expected to continue at least through mid-2020s
- Lenacapavir’s potential 6-month dosing transforms PrEP market starting in mid-2020s
- Gilead’s multiple long-acting options to launch and reshape treatment market after 2027

Dynamics to Manage

- Long-acting competition
- Descovy LOE

Targeting HIV Lifecycle With Long-Acting Portfolio

1. Virus Entry
2. Reverse Transcription
3. Nuclear Entry & Capsid Disassembly
4. Integration
5. Assembly & Budding
6. Maturation

**Virus Entry**
- GS-2872 + GS-5423
  - Class: bNAb
  - Phase: 1b
- bNAb
  - Class: bNAb
  - Phase: Exploratory

**Reverse Transcription**
- Islatravir
  - Class: NRTI
  - Phase: 2
- GS-5894
  - Class: NNRTI
  - Phase: 1
- GS-1614
  - Class: NRTI
  - Phase: Pre-IND
- LA Tenofovir
  - Class: NRTI
  - Phase: Discovery

**Nuclear Entry & Capsid Disassembly**
- Lenacapavir
  - Class: CAI
  - Phase: Z-3, NDA
- GS-4182
  - Class: CAI
  - Phase: Pre-IND
- Multiple Capsid Programs
  - Class: CAI
  - Phase: Discovery

**Integration**
- LA Bictegravir
  - Class: INSTI
  - Phase: 1
- GS-1720
  - Class: INSTI
  - Phase: Pre-IND
- GS-6212
  - Class: INSTI
  - Phase: Pre-IND
- INSTI
  - Class: INSTI
  - Phase: Discovery

**Assembly & Budding**
- GS-1156
  - Class: PI
  - Phase: Discovery

1. Merck's investigational islatravir. Note: bNAb - Broadly neutralizing antibody; CAI - Capsid assembly inhibitor; IND - Investigational new drug; INSTI - Integrase strand transfer inhibitor; LA - Long-acting; NDA - New drug application; NRTI - Nucleoside reverse transcriptase inhibitor; NNRTI - Non-nucleoside reverse transcriptase inhibitor; PI - Protease inhibitor.
### Long-Acting Pipeline Positioned To Be Best-in-Disease

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosing Every</td>
<td>Dosing Every</td>
</tr>
<tr>
<td>Foundation</td>
<td>Foundation</td>
</tr>
<tr>
<td>Partner</td>
<td>Partner</td>
</tr>
</tbody>
</table>

- **Lenacapavir** + [NNRTI](#) 
  - Phase 1
- **Lenacapavir** + [Istratavir](#) 
  - Phase 1
- **Lenacapavir** + [LA Bictegravir](#) 
  - Phase 1
- **Lenacapavir** + [Istratavir](#) 
  - IND TBD
- **Lenacapavir** + [2 bNabs](#) 
  - Phase 1b POC

#### Potential Approval in 2025

- **6 Months**
  - [Lenacapavir](#)
  - [PURPOSE 1 and 2](#)
  - Phase 3

---

*Note: Lenacapavir is an investigational agent and is not approved by any regulatory authority for any use; its safety and efficacy are not established. Merck’s Istratavir is an investigational agent and is not approved by any regulatory authority for any use; its safety and efficacy are not established. 1 FDA has placed a partial clinical hold on the Phase 2 long-acting oral trial of lenacapavir and Merck’s Istratavir.*

Presented strong lenacapavir 6-month efficacy data for HTE population; NDA submitted.

---

*“With 6-month dosing, if approved, lenacapavir would have the potential to be a true game changer.”*  
  
  -- Monica Gandhi, MD, MPH; Professor of Medicine, Division of HIV, Infectious Disease and Global Medicine, UCSF; Director: UCSF Center for AIDS Research
Applying Antiviral Expertise to COVID-19 and Beyond

Veklury®
remdesivir

87%
Reduction in risk for hospitalization in investigational PINETREE study¹

3 in 5
Hospitalized COVID-19 patients in U.S. receive Veklury²

~10M
Patients treated globally³

127
Countries with distribution access⁴

Growth of Virology Pipeline

- HIV cure / remission
- Viral Hepatitis
- Respiratory Viruses
- Pandemic / Emerging Viruses
- Herpesviruses

Oral COVID-19 remdesivir pro-drug IND cleared with Phase 1 initiation expected in Q122.

¹ Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 compared with placebo; no deaths occurred in either arm of the study through the primary endpoint. Results from Phase 3 PINETREE Study in non-hospitalized patients at high risk of disease progression. Source: Gottlieb et al (NEJM 2021). In the U.S., the use of Veklury for non-hospitalized patients is investigational; this use has not been approved by the U.S. FDA. ² Hospitalized patients treated and utilization estimates are based on global Veklury, global remdesivir, and generic remdesivir volume donated and shipped for distribution. ³ Patients treated and utilization estimates are based on global Veklury, global remdesivir, and generic remdesivir volume donated and shipped for distribution. Within the US, assumed average treatment course is 5.5 vials/patient and ex-US, assumed average treatment course is 6.25 vials/patient. ⁴ Countries with distribution access is through voluntary licensing.
Oncology Revenue Growing to Exceed $1B in 2021

Key Anticipated Milestones

- 97% manufacturing reliability
- ~42% YoY\(^1\) growth

$632M
Q321 YTD SALES\(^2\)

Key Anticipated Milestones

- 2L LBCL sBLA decision in 1H22, MAA in 2H22
- ALL and iNHL MAA decisions in 2022
- Maryland manufacturing site online mid-2022

$262M
Q321 YTD SALES\(^2\)

Key Anticipated Milestones

- Launched in 2L mTNBC and 2L mUC
- 2L mTNBC new patient starts increased to 1 in 4\(^3\)

Note: Yescarta (axicabtagene ciloleucel) for IV infusion, Tecartus (brexucabtagene autoleucel) for IV infusion, and Trodelvy (sacituzumab govitecan-hziy) for injection. ALL - acute lymphocytic leukemia. FL - follicular lymphoma. LBCL - large B cell lymphoma. sBLA - Supplemental biologics license application. MAA - Marketing authorization application. mTNBC - Metastatic triple negative breast cancer. FDA approval received for 2L mTNBC in April 2021, followed by approvals in EU, Switzerland, Canada, Australia, and Great Britain. FDA granted accelerated approval for 2L mUC in April 2021. \(^1\) YoY - Year-over-year growth for Q1-Q3 2021 vs Q1-Q3 2020. \(^2\) Q321 YTD reflects Q1-Q3 2021 performance. \(^3\) Source: IQVIA. This information is an estimate derived from the use of information under license from the following IQVIA information service: LAAD claims for the period October 2021. IQVIA expressly reserves all rights, including rights of copying, distribution and republication.
Delivering a World-Class Oncology Portfolio

Today

18
Oncology Assets

>30
Oncology Clinical Trials

13
New Clinical Trial Initiations in 2021

By 2030

✓ Clear pathway to deliver 20+ transformative indication approvals

✓ Positively impact 400,000+ patient lives

✓ Expect oncology to be at least a third of total revenues

Establishing Robust Portfolio

• Portfolio rich with opportunities for combinations

• Doubled the talent dedicated to oncology\(^1\)

Oncology Scientific Framework Shaping Pipeline

**Trigger Tumor-Intrinsic Cell Death**
- Antibody-Drug Conjugate
  - TROP2
    - Trodelvy
- Tumor Cell Apoptosis
  - MCL-1
    - GS-9716

**Promote Immune-Mediated Tumor-Killing**
- T & NK Cell Checkpoint and Co-Stimulation
  - TIGIT
domvanalimab & AB308
  - PD-1
    - zimberelimab
- HLA-G
  - TTX-080
  - AGEN2373
- CD19 CAR-T
  - Yescarta
  - Tecartus
- CD19/20 CAR-T
  - KITE-363
  - KITE-222

**Engineered T-cells**
- CD19 CAR-T
  - Yescarta
  - Tecartus
- CD19 CAR-T
  - KITE-363
  - KITE-222
- PLL3R
  - GS-3583

**Remodel Tumor-Permissive Microenvironment**
- Macrophage-Mediated Immuno-Suppression
  - TREM1
    - PY-159
  - TREM2
    - PY-314
- Adenosine-Mediated Immuno-Suppression
  - A2A/A2B
    - etrumadenant
  - CD73
    - quemliclustat
- Treg-Mediated Immuno Suppression
  - CCR8
    - GS-1811

**Note:** Gilead and Arcus will co-develop and co-commercialize domvanalimab and AB308, zimberelimab, etrumadenant, and quemliclustat. Gilead has the exclusive rights to develop and commercialize Jounce’s anti-CCR8 antibody, referred to as GS-1811. Gilead has exclusive options to acquire Tizona, including its TTX-080, and Pionyr, including its PY-159 and PY-314. Gilead has the exclusive rights to opt-in for Agenus’ AGEN2373.
Combination Potential For Novel Oncology Portfolio

**Trigger Tumor-Intrinsic Cell Death**
- TROP2
  - Trodelvy
- MCL1
  - GS-9716

**Promote Immune-Mediated Tumor-Killing**
- CD47
  - magrolimab
- CD19
  - Yescarta/ Tecartus
- CD19/20
  - KITE-363
- CLL1
  - KITE-222
- TIGIT
  - domvanalimab & AB308
- PD-1
  - zimberelimab
- SIRPα
  - GS-0189
- CD137
  - AGEN2373
- FLT3R
  - GS-3583
- HLA-G
  - TTX-080
- PD-1
  - zimberelimab
- CD19/20
  - KITE-363
- PD-1
  - zimberelimab
- SIRPα
  - GS-0189
- CD137
  - AGEN2373

**Remodel Tumor-Permissive Microenvironment**
- A2A R/A2B R
  - etrumadenant
- CD73
  - quemliclustat
- CCR8
  - GS-1811
- TREM1
  - PY-159
- TREM2
  - PY-314

**Active and Potential Combinations**

1. TIGIT
   - domvanalimab
   - zimberelimab
2. PD-1
   - etrumadenant
3. TROPE
   - Trodelvy
4. CCR8
   - GS-1811
5. PD-1
   - zimberelimab
6. TROPE
   - Trodelvy
7. CD47
   - magrolimab

Note: Gilead and Arcus will co-develop and co-commercialize domvanalimab and AB308, zimberelimab, etrumadenant, and quemliclustat. Gilead has the exclusive rights to develop and commercialize Jounce’s anti-CCR8 antibody, referred to as GS-1811. Gilead has exclusive options to acquire Tizona, including its TTX-080, and Pionyr, including its PY-159 and PY-314. Gilead has the exclusive rights to opt-in for Agenus’ AGEN2373. 1 Actively explored combinations: domvanalimab + zimberelimab + etrumadenant + TROPE + Tizona. Potential combinations to explore: GS-188 + zimberelimab + Trodelvy + magrolimab.
Expanding Across Breadth of Indications

**Solid Tumors**

- Triple-Negative Breast Cancer
- Bladder Cancer
- HR+ / HER2-Breast Cancer
- Non-Small Cell Lung Cancer
- Head and Neck Cancer
- Prostate Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Endometrial Cancer
- Small Cell Lung Cancer
- Gastric and Gastroesophageal Junction Cancer
- Cervical Cancer
- Ovarian Cancer
- Renal Cell Carcinoma

**Hematological Cancers**

- Large B-cell Lymphoma
- Follicular Lymphoma
- Acute Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Multiple Myeloma
- Chronic Lymphocytic Leukemia

Select Partnerships:

- agenus
- APPRIA BIO
- ARC BIOSCIENCES
- JOUNCE
- MERCK
- PIONYR IMMUNOTHERAPEUTICS
- SHORELINE BIOSCIENCES
- TIZONA BIOSCIENCES

---

1 Trodelvy received full approval for 2L metastatic triple-negative breast cancer in the US, EU, and Project Orbis countries; Trodelvy received accelerated approval for 2L metastatic urothelial cancer in the US.
2 Yescarta is approved for 3L+ relapsed/refractory (R/R) large B-cell lymphoma in the US and EU, among others, and received accelerated approval in 3L+ R/R follicular lymphoma in the US. Tecartus was granted accelerated approval for R/R mantle cell lymphoma in the US and EU, and full approval for R/R adult acute lymphoblastic leukemia.
## Strong Oncology Pipeline Execution and Expansion

### >30 clinical trials today

- **13 new trial starts in 2021**
- **4 with Breakthrough Therapy Designation**
  - Trodelvy 2L mTNBC
  - Magrolimab 1L HR MDS
  - Yescarta r/r FL
  - Tecartus adult ALL
- **4 Approvals in 2021**
  - Trodelvy in 2L mTNBC
  - Tecartus in adult ALL
  - Trodelvy in 2L mUC (accelerated)
  - Yescarta in r/r FL (accelerated)

### >20 new trials planned to initiate in 2022

(Includes Gilead-sponsored or partnered / co-developed studies expected to start in 2022)

<table>
<thead>
<tr>
<th>Approved</th>
<th>2L mTNBC</th>
<th>Approved</th>
<th>2L mUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph3</td>
<td>HR+/HER2- mBC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph3</td>
<td>2-3L NSCLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph3</td>
<td>Solid Tumor Basket</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph3</td>
<td>1L mTNBC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Domvanalimab**

- TIGIT

<table>
<thead>
<tr>
<th>Ph3</th>
<th>1L NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph2</td>
<td>Stage 3 NSCLC</td>
</tr>
<tr>
<td>Ph3</td>
<td>Lung</td>
</tr>
<tr>
<td>Ph3</td>
<td>GI</td>
</tr>
<tr>
<td>Ph3</td>
<td>TBD</td>
</tr>
</tbody>
</table>

**Magrolimab**

- CD47

<table>
<thead>
<tr>
<th>Ph3</th>
<th>1L HR MDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph3</td>
<td>1L AML</td>
</tr>
<tr>
<td>Ph3</td>
<td>1L Unfit AML</td>
</tr>
<tr>
<td>Ph2</td>
<td>HNSCC</td>
</tr>
<tr>
<td>Ph2</td>
<td>MM</td>
</tr>
<tr>
<td>Ph2</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Ph2</td>
<td>TNBC</td>
</tr>
<tr>
<td>Ph2</td>
<td>DLBCL</td>
</tr>
<tr>
<td>Ph2</td>
<td>Colorectal</td>
</tr>
<tr>
<td>Ph1/2</td>
<td>Prostate</td>
</tr>
</tbody>
</table>

Upcoming Investor Events

1 FEB
Q4 & FY Results
Tuesday, 1 February 2022

17 FEB
Virology Deep Dive
Thursday, 17 February 2022

14 APR
Oncology Deep Dive
Thursday, 14 April 2022
**Looking Forward: Diversified, Sustainable Growth**

<table>
<thead>
<tr>
<th>TODAY</th>
<th>2030</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Growing HIV revenues</td>
<td>• Expanding virology leadership: expect stable or growing HIV business</td>
</tr>
<tr>
<td>• Executing on oncology strategy, tracking to exceed $1B in revenue</td>
<td>• Delivering a world-class oncology portfolio: expect to be a third of revenues</td>
</tr>
<tr>
<td>• Nearly doubled clinical pipeline</td>
<td>• Targeting 10+ transformative therapies by 2030</td>
</tr>
<tr>
<td>• Key role in helping to combat COVID</td>
<td></td>
</tr>
</tbody>
</table>
APPENDIX
## Robust Pipeline with Upcoming Catalysts

<table>
<thead>
<tr>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3, FILED, or APPROVED</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magrolimab anti-CD47²</td>
<td>Sacituzumab govitecan-hziy Basket study (incl. NSCLC)</td>
<td>Sacituzumab govitecan-hziy 1L mTNBC (PD-L1+)</td>
</tr>
<tr>
<td>Magrolimab anti-CD47 Solid Tumors</td>
<td>Magrolimab anti-CD47 HNSCC</td>
<td>Sacituzumab govitecan-hziy 2-3L NSCLC</td>
</tr>
<tr>
<td>Etruma combinations (ARC-9) mCRC</td>
<td>Magrolimab anti-CD47 AM</td>
<td>Magrolimab anti-CD47 1L HR AML</td>
</tr>
<tr>
<td>Etruma combinations (ARC-6)² mCRC</td>
<td>Magrolimab anti-CD47 TNBC</td>
<td>Magrolimab anti-CD47 1L mBC</td>
</tr>
<tr>
<td>Dom + zim ± etruma (ARC-7) NSCLC</td>
<td>Brexu-cell Pediatric ALL</td>
<td>Dom + zim vs. zim vs. chemo (ARC-10) 1L NSCLC</td>
</tr>
<tr>
<td>Yescarta® (axi-cel) IL LBC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Viral Disease** | | |
| Lenacapavir/Islatravir oral combination HIV LA V5 | Vesatolimod TLR-7 agonist HIV Cure | Lenacapavir capsid inhibitor HIV PrEP |
| | Lefitolimod TLR-9 agonist HIV Cure | Hepcludex® (bulevtiride)³ HDV |
| | Lenacapavir capsid inhibitor HIV LA HTE | Veklury® (remdesivir) COVID-19 Outpatient |
| | bNAb combination HIV Cure | Hepcludex® (bulevtiride) HDV |
| | Selgantolim TLR-8 agonist HIV Cure | |

| **Inflammatory Disease** | | |
| Galapagos 7 clinical stage programs³ | Selonsertib ASK1 inhibitor DDI | Cilofexor/ firsocostat/ semaglutide combination NASH |
| | Cilofexor FXR agonist PSC | Filgotinib JAK-1 Inhibitor Crohn’s Disease |
| | | Filgotinib JAK-1 Inhibitor Ulcerative Colitis |

### FDA approved medicines shown:
- Trodelvy® for 2L mTNBC, Trodelvy® for 2L mUC (accelerated approval), Yescarta® for 3L LBC, Yescarta® R/R FL, Tecartus® for Adult ALL and MCL (accelerated approval), Veklury® for COVID-19.

### Clinical stage programs¹

### NDA/BLA/MAA filings, P3 and registrational P2

### Potential clinical stage opt-in assets

---


---

The table outlines the pipeline of clinical stage programs for different diseases, including oncology, viral, and inflammatory conditions. The FDA-approved medicines listed include Trodelvy® for 2L mTNBC, Trodelvy® for 2L mUC (accelerated approval), Yescarta® for 3L LBC, Yescarta® R/R FL, Tecartus® for Adult ALL and MCL (accelerated approval), Veklury® for COVID-19. The pipeline includes six Phase 1 clinical stage programs and one Phase 2 clinical stage program for diseases such as acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), axicabtagene ciloleucel (axi-cel), axicabtagene autoleucel (bNAb), brexucabtagene autoleucel (bexu-cel), and durvalumab (durva). The table also highlights the potential clinical stage opt-in assets and the optionable partner program.